Lquin

Lquin Tablet is an antibiotic medicine. It is used for the treatment of bacterial infection of the lungs, throat, airways, nose, ears, urinary tract, skin and soft tissues. It contains levofloxacin.

Product dosage: 250mg
Package (num)	Per pill	Price	Buy
90	$0.53	$48.00 (0%)	🛒 Add to cart
120	$0.48	$64.00 $58.00 (9%)	🛒 Add to cart
180	$0.43	$96.00 $77.00 (20%)	🛒 Add to cart
270	$0.32	$144.00 $86.00 (40%)	🛒 Add to cart
360	$0.29 Best per pill	$192.00 $104.00 (46%)	🛒 Add to cart

Lquin (levofloxacin) is a broad-spectrum fluoroquinolone antibiotic indicated for the treatment of adults with complicated and uncomplicated bacterial infections. Developed through rigorous pharmaceutical research, Lquin demonstrates potent bactericidal activity against a wide range of Gram-positive and Gram-negative pathogens, including multidrug-resistant strains. Its optimized pharmacokinetic profile ensures high tissue penetration and sustained therapeutic concentrations, making it a first-line option in hospital and community settings where resistant organisms are suspected. Clinical evidence supports its efficacy in lower respiratory tract, urinary tract, skin, and intra-abdominal infections, providing clinicians with a reliable therapeutic tool in complex cases.

Features

• Active ingredient: Levofloxacin 250 mg, 500 mg, or 750 mg film-coated tablets
• Mechanism: Inhibition of bacterial DNA gyrase and topoisomerase IV
• Spectrum: Broad activity against aerobic Gram-positive and Gram-negative bacteria
• Bioavailability: Approximately 99% oral absorption, unaffected by food
• Half-life: 6–8 hours, allowing for once or twice-daily dosing
• Excretion: Primarily renal, requiring dosage adjustment in impaired renal function

Benefits

• Rapid bactericidal action leading to quicker symptomatic relief and shorter infection duration
• High bioavailability and tissue penetration ensure effective drug delivery to infection sites
• Convenient once-daily dosing regimen improves patient adherence and treatment outcomes
• Proven efficacy against common and resistant pathogens reduces the need for combination therapy
• Well-established safety profile with extensive clinical use across multiple infection types
• Available in multiple strengths for tailored dosing based on infection severity and patient factors

Common use

Lquin is commonly prescribed for the treatment of acute bacterial exacerbations of chronic bronchitis, community-acquired pneumonia, complicated and uncomplicated urinary tract infections, acute pyelonephritis, and skin and skin structure infections. It is also used in the management of nosocomial pneumonia, chronic bacterial prostatitis, and as part of combination therapy for certain intra-abdominal infections. Off-label uses may include treatment of certain sexually transmitted infections and orthopedic infections, though these should only be considered when supported by culture and susceptibility data and when alternative therapies are unsuitable.

Dosage and direction

The recommended dosage of Lquin varies based on the type and severity of infection, renal function, and patient characteristics. For most infections in adults with normal renal function (creatinine clearance >50 mL/min), the typical dose is 250–750 mg orally or intravenously once daily. Treatment duration generally ranges from 7 to 14 days, though some infections may require longer therapy. Administration should occur at the same time each day, with or without food, with adequate hydration. Tablets should be swallowed whole and not crushed or chewed. For patients with renal impairment, dosage adjustment is necessary based on creatinine clearance:

• CrCl 20–49 mL/min: Administer initial dose of 500 mg, then 250 mg every 24 hours
• CrCl 10–19 mL/min: Administer initial dose of 500 mg, then 250 mg every 48 hours

Precautions

Patients should be advised to complete the full course of therapy even if symptoms improve, to prevent development of resistance. Lquin should be used with caution in elderly patients due to increased risk of tendon disorders and central nervous system effects. Adequate hydration should be maintained during treatment to prevent crystal formation. Patients should avoid excessive sunlight or artificial UV exposure due to photosensitivity reactions. Blood glucose monitoring is recommended in diabetic patients, as dysglycemia has been reported. Neurological monitoring is advised in patients with known or suspected central nervous system disorders. Regular assessment of renal and hepatic function is recommended during prolonged therapy.

Contraindications

Lquin is contraindicated in patients with known hypersensitivity to levofloxacin, other quinolone antibiotics, or any component of the formulation. It should not be used in patients with a history of tendon disorders associated with quinolone use. Contraindicated in patients with myasthenia gravis due to potential exacerbation of muscle weakness. Not recommended during pregnancy (Category C) unless potential benefits outweigh risks. Should not be used in nursing mothers unless absolutely necessary. Contraindicated in pediatric patients and adolescents under 18 years except for specific indications where benefits outweigh risks of musculoskeletal disorders.

Possible side effect

Common adverse reactions (≥1%) include nausea, diarrhea, headache, insomnia, constipation, and dizziness. Less frequent but potentially serious side effects include tendonitis and tendon rupture (particularly Achilles tendon), peripheral neuropathy, central nervous system effects (seizures, anxiety, confusion), QT interval prolongation, hypoglycemia, hepatic toxicity, and photosensitivity reactions. Clostridium difficile-associated diarrhea may occur during or after treatment. Hematologic abnormalities including leukopenia and eosinophilia have been reported. Allergic reactions ranging from rash to anaphylaxis may occur. Musculoskeletal disorders including arthralgia and myalgia have been observed.

Drug interaction

Lquin may interact with several classes of medications. Concurrent use with corticosteroids increases risk of tendon rupture. Antacids containing magnesium, aluminum, iron, or zinc significantly reduce absorption and should be administered at least 2 hours before or after Lquin. Sucralfate and multivitamins containing zinc or iron should be similarly spaced. QT-prolonging agents (antiarrhythmics, antipsychotics, antidepressants) may increase risk of torsades de pointes. Nonsteroidal anti-inflammatory drugs may enhance CNS stimulation and seizure risk. Warfarin requires close INR monitoring due to potential enhancement of anticoagulant effect. Diabetic medications may require adjustment due to potential hypoglycemic effects. Probenecid may decrease renal clearance of levofloxacin.

Missed dose

If a dose is missed, it should be taken as soon as remembered unless it is almost time for the next scheduled dose. In that case, the missed dose should be skipped and the regular dosing schedule resumed. Patients should not double the dose to make up for a missed administration. Consistency in dosing is important to maintain therapeutic drug levels, so patients should be advised to use reminder systems if adherence is a concern. Healthcare providers should be notified if multiple doses are missed, as this may compromise treatment efficacy and contribute to antibiotic resistance.

Overdose

Symptoms of overdose may include dizziness, tremor, nausea, vomiting, and seizures. ECG monitoring is recommended due to potential QT prolongation. Management is primarily supportive, with careful observation and symptomatic treatment. Hemodialysis removes approximately 10–20% of the drug and may be considered in severe cases, though its effectiveness is limited. Gastric lavage may be beneficial if performed soon after ingestion. No specific antidote exists. Patients should be monitored for at least 24–48 hours due to the drug’s half-life. Serum electrolyte levels should be checked and corrected if abnormal. Cardiac monitoring should continue until ECG parameters normalize.

Storage

Store at controlled room temperature (20–25°C or 68–77°F) in the original container. Protect from light and excessive moisture. Keep tightly closed and out of reach of children. Do not store in bathroom or other humid areas. Do not use if the seal is broken or tablets show signs of deterioration. Dispense in original container with child-resistant closure. Do not transfer to other containers as this may affect stability. Properly discard any unused medication after completion of therapy or expiration date.

Disclaimer

This information is provided for educational purposes only and does not constitute medical advice. Lquin is a prescription medication that should only be used under the supervision of a qualified healthcare professional. The prescribing physician should be consulted for specific medical advice, diagnosis, and treatment. Individual patient response may vary, and not all side effects or interactions are listed here. Healthcare providers should reference the complete prescribing information before administration. The manufacturer is not responsible for misuse or incorrect interpretation of this information.

Reviews

Clinical studies demonstrate Lquin’s efficacy with clinical success rates of 85–95% across various infection types. In a multicenter trial of community-acquired pneumonia (n=1,243), Lquin 500 mg daily achieved 96% clinical cure rate at test-of-cure visit. For complicated urinary tract infections, studies show microbiological eradication rates of 89–93% against common uropathogens. Post-marketing surveillance data indicate satisfactory tolerability profile with discontinuation rates due to adverse events of approximately 4%. Many infectious disease specialists note its reliability in empiric therapy for healthcare-associated infections where resistance patterns are concerning. Some clinicians express caution regarding tendon toxicity in elderly patients but acknowledge the favorable risk-benefit ratio in appropriate clinical scenarios.